Horizon Pharma Plc (HZNP) Shareholder Cam Group Holding A Cut Its Position as Stock Price Rose

Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) LogoInvestors sentiment increased to 1.33 in 2018 Q4. Its up 0.47, from 0.86 in 2018Q3. It is positive, as 27 investors sold HZNP shares while 60 reduced holdings. 54 funds opened positions while 62 raised stakes. 136.51 million shares or 1.16% more from 134.96 million shares in 2018Q3 were reported. California State Teachers Retirement System invested in 262,873 shares. Rhenman & Prtnrs Asset Mngmt Ab has 946,060 shares. Moreover, Dekabank Deutsche Girozentrale has 0.01% invested in Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) for 52,000 shares. Manufacturers Life The holds 0% or 112,976 shares in its portfolio. Minnesota-based Kopp Inv Lc has invested 2.79% in Horizon Therapeutics Public Limited Company (NASDAQ:HZNP). Leavell Invest Management holds 0.02% or 10,000 shares. Capital Fund Management owns 348,227 shares or 0.06% of their US portfolio. Intrust Commercial Bank Na accumulated 14,658 shares or 0.08% of the stock. Bnp Paribas Arbitrage Sa holds 0% or 69,557 shares in its portfolio. Quantitative Inv Management Limited Liability Corporation holds 0.02% in Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) or 21,800 shares. Rothschild Asset Management Us holds 0.39% or 1.66M shares. Moody Bancorporation Trust Division has 0% invested in Horizon Therapeutics Public Limited Company (NASDAQ:HZNP). 169,300 are held by State Of Wisconsin Invest Board. Adams Diversified Equity Fund Inc holds 20,000 shares. Farmers & Merchants invested in 0% or 343 shares.

Since November 14, 2018, it had 0 insider purchases, and 1 insider sale for $204,559 activity. Walbert Timothy P also sold $8.80 million worth of Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) on Wednesday, November 14.

Cam Group Holding A decreased its stake in Horizon Pharma Plc (HZNP) by 45.48% based on its latest 2018Q4 regulatory filing with the SEC. Cam Group Holding A sold 159,805 shares as the company’s stock rose 36.97% with the market. The institutional investor held 191,544 shares of the major pharmaceuticals company at the end of 2018Q4, valued at $3.74M, down from 351,349 at the end of the previous reported quarter. Cam Group Holding A who had been investing in Horizon Pharma Plc for a number of months, seems to be less bullish one the $4.78B market cap company. The stock decreased 4.19% or $1.13 during the last trading session, reaching $25.83. About 1.15 million shares traded. Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) has risen 89.51% since May 17, 2018 and is uptrending. It has outperformed by 85.14% the S&P500.

More notable recent Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) news were published by: Finance.Yahoo.com which released: “Did Hedge Funds Drop The Ball On Taro Pharmaceutical Industries Ltd. (TARO)? – Yahoo Finance” on April 25, 2019, also Businesswire.com with their article: “Horizon Therapeutics plc Announces Tina Ventura as a Healthcare Businesswomen’s Association 2019 Luminary – Business Wire” published on May 09, 2019, Nasdaq.com published: “HZNP April 18th Options Begin Trading – Nasdaq” on January 15, 2019. More interesting news about Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) were released by: Nasdaq.com and their article: “Horizon Pharma (HZNP) Earnings Expected to Grow: What to Know Ahead of Next Week’s Release – Nasdaq” published on February 20, 2019 as well as Nasdaq.com‘s news article titled: “What’s in Store for BioDelivery (BDSI) This Earnings Season? – Nasdaq” with publication date: May 02, 2019.

Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) Ratings Coverage

Among 5 analysts covering Horizon Pharma Inc (NASDAQ:HZNP), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Horizon Pharma Inc had 11 analyst reports since February 27, 2019 according to SRatingsIntel. Cantor Fitzgerald maintained Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) on Wednesday, February 27 with “Buy” rating. The stock has “Overweight” rating by Cantor Fitzgerald on Wednesday, April 3. The stock of Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) earned “Buy” rating by Jefferies on Thursday, February 28. As per Wednesday, February 27, the company rating was maintained by Mizuho. The company was maintained on Thursday, February 28 by Cowen & Co. The firm earned “Buy” rating on Friday, March 1 by JMP Securities. On Monday, March 4 the stock rating was maintained by Morgan Stanley with “Hold”.

Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.